AbbVie, Teneobio link to develop multiple myeloma drug
AbbVie has signed a deal with Teneobio to develop a B-cell maturation antigen (BCMA)-targeting bispecific antibody for multiple myeloma.
Read More
Tag: Teneobio
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
